Javelin Biotech Aims to Develop Industry-Leading "Organ-on-a-Chip" Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.

Collaboration aims to create the first "organ-on-a-chip" system specifically designed for human PK predictions

Javelin Biotech ("Javelin") today announces a three-year collaboration with Pfizer Inc. (NYSE: PFE) to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules. The ADME platform will integrate a microphysiological system (MPS), commonly referred to as "organ-on-a-chip," with interactive computational software to help inform human pharmacokinetic (PK) predictions, a key measure in evaluating new drug candidates in preclinical research. If successful, Javelin plans to commercialize the platform for broad industry adoption; it would potentially be the first "organ-on-a-chip" system on the market specifically designed for human PK predictions.

Under terms of the agreement, the companies will bring together Javelin's in-depth tissue engineering and microfluidics expertise and Pfizer's leading expertise in human PK predictions to create the ADME platform. Javelin will design, build and test the platform, and Pfizer will provide industry guidance for real-world usage, as well as drug and data sets to help validate the platform's predictions. Javelin will retain any potential commercialization rights to the platform. Financial details were not disclosed.

The platform aims to provide insights into how drugs perform in humans and supports quantitative decision making, including to predict PK parameters across sub-populations and to guide first-in-human dosing strategy for Phase I clinical trial design.

The ADME platform will comprise an MPS system that contains chambers for the four most important human tissues involved in drug disposition (liver, kidney, intestine, and tissue distribution), as well as a microflow pumping system that circulates media among the compartments. The system will be coupled with a computational algorithm that will translate the data to a physiologically based model of human PK.

Current efforts in preclinical drug development characterize ADME properties of drug candidates with in vitro systems and animal models, both of which often have drawbacks. Human cell-based in vitro systems often lack the complexity to replicate tissue cytostructure and function. While animal models offer more complexity, they often lack human relevance. The Javelin team has published multiple papers supporting the use of interconnected, human tissue cultures with the complexity and relevance to estimate ADME parameters and to translate to human clinical PK profiles.

"At Javelin, we develop predictive solutions to address a range of bottlenecks in preclinical drug discovery. The human ADME platform that we aim to create is a great example of the power of our approach combining bioengineering with data sciences. We are excited to work with Pfizer's ADME scientists through this collaboration," said Dr. Murat Cirit, CEO of Javelin Biotech. "With recent advances in microphysiological systems, Javelin and Pfizer share a common vision and see an opportunity to design a platform that delivers human ADME parameters in a time, cost, and scale that can improve current lead optimization and candidate nomination practices."

"This collaboration between Pfizer and Javelin has the potential to lead to a transformational change in how we evaluate human pharmacokinetics, without dosing humans," said Charlotte Allerton, Head of Medicine Design, Pfizer. "PK predictions are a fundamental element in how we prioritize emerging therapies to move into the clinical stage of development, and a platform such as the one we aim to create will give us higher confidence as we choose candidates that we hope will ultimately develop into breakthroughs that change patients' lives."

For more information, email kevin@javelinbio.com and visit www.javelinbio.com

About Javelin Biotech:

Javelin Biotech is a venture-backed company spun out from Dr. Murat Cirit's lab at MIT. The company develops predictive preclinical drug discovery platforms integrating human complex in vitro models and data science for ADME applications and to study neurodegenerative diseases and liver/metabolic diseases. These platforms deliver actionable insights, time savings, and cost savings to pre-clinical drug discovery & development teams. Javelin Biotech is located in Woburn, Massachusetts.

Kevin O'Handley  
Javelin Biotech, Inc.  
(781) 995-3099  
kevin@javelinbio.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing -
  - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -
  - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -
  - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -
  - PTC will host a conference call on Dec. 2, 2024 , at 8:30 am EST -

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio to receive upfront, and potential milestones and tiered royalty payments

Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Pill spelling "big pharma."

Big Pharma Stocks Eli Lilly, AbbVie and Pfizer Share Q3 Results

Major pharmaceutical players Eli Lilly (NYSE:LLY), AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) reported mixed Q3 results, with each company facing distinct market forces, ranging from supply issues to financial constraints.

In its latest quarterly report, released on Wednesday (October 30), Eli Lilly missed on sales expectations for Zepbound, its popular weight-loss drug, and Mounjaro, its diabetes medication. Despite growing US demand for these products, supply chain management issues impacted the company’s ability to meet Wall Street's expectations.

According to Reuters, Eli Lilly dropped 8 percent on the news, reducing its market valuation by nearly US$70 billion.

Keep reading...Show less
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical company is diverse and dynamic.

Canadian pharma companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Here the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXV and CSE by year-to-date gains. All data was compiled on October 28, 2024, using TradingView’s stock screener, and the companies considered had market caps above C$10 million at that time. Read on to learn about what's been driving their share prices.

Keep reading...Show less

Latest Press Releases

Related News

×